Novartis' Lescol Patent Enforceable, Judge Says
A federal judge has shot down Mylan Pharmaceuticals Inc.'s bid to manufacture a generic version of Novartis Pharmaceuticals Corp.'s anti-cholesterol drug Lescol, ruling that a patent covering the treatment is enforceable....To view the full article, register now.
Already a subscriber? Click here to view full article